AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
182.31
-4.48 (-2.40%)
At close: Jun 27, 2025, 4:00 PM
183.00
+0.69 (0.38%)
After-hours: Jun 27, 2025, 7:59 PM EDT
AbbVie Employees
AbbVie had 55,000 employees as of December 31, 2024. The number of employees increased by 5,000 or 10.00% compared to the previous year.
Employees
55,000
Change (1Y)
5,000
Growth (1Y)
10.00%
Revenue / Employee
$1,043,036
Profits / Employee
$75,545
Market Cap
322.03B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ABBV News
- 2 days ago - Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 2 days ago - My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys - Seeking Alpha
- 3 days ago - 2 Dividend Aristocrats Bargains To Buy And 'Never Let Go' - Seeking Alpha
- 4 days ago - 3 dividend stocks investors can look for stability as Iran attacks US base in Qatar - Invezz
- 7 days ago - I'm Buying Dividend Giants At Huge Discounts - Seeking Alpha
- 7 days ago - AbbVie Declares Quarterly Dividend - PRNewsWire
- 9 days ago - AbbVie's migraine drug meets main goal of late-stage study - Reuters
- 9 days ago - AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - PRNewsWire